Ferguson GT, et al. - Experts investigated the pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in subjects having moderate-to-very severe COPD. The accumulation of glycopyrronium and formoterol associated with GFF MDI, glycopyrronium (GP) MDI, and formoterol fumarate dihydrate (FF) metered dose inhaler (MDI) was characterized in the findings, indicating that after treatment with GFF MDI formulated using co-suspension delivery technology, there were no meaningful PK interactions, whether drug-drug or due to formulation, between glycopyrronium and formoterol.